One To Watch

Norgine

Company Overview

A century-old European specialty pharmaceutical company headquartered in the Netherlands, Norgine acquires, develops, and commercializes innovative products across gastroenterology, hepatology, oncology, and rare diseases. Founded in 1906 and now backed by Goldman Sachs, the company operates a fully integrated commercial infrastructure spanning Europe, Australia, and New Zealand. Norgine has built its reputation as a partner of choice for innovative companies seeking trusted in-licensing and commercialization capabilities across these markets.

Headquarters and Global Presence

Norgine is headquartered in Amsterdam, Netherlands, with a broad commercial footprint across European markets and operations extending to Australia and New Zealand. The company employs approximately 1,155 people and manages a global network of licensing and distribution partnerships that reaches markets including South Korea and Japan.

Founding and History

Norgine was established in 1906 by founder Stein, who combined the words "north" and "alginate" to name the company after acquiring a seaweed-processing facility in Brittany, France. Over the following century, the company evolved from alginate extraction into a fully diversified specialty pharmaceutical operator. Key milestones include the acquisition of specialty biopharmaceutical firm Azanta in June 2024, the $342 million acquisition of Merus Labs International, and the European Commission's approval of Goldman Sachs's acquisition of Norgine Group, also completed in June 2024.

Therapy Areas and Focus

Norgine's core therapeutic focus spans gastroenterology, hepatology, oncology, and rare diseases. In gastroenterology and hepatology, the company markets bowel preparation agent Plenvu and rifaximin-α (Xifaxan) for hepatic encephalopathy, where real-world IMPRESS data demonstrated meaningful reductions in non-elective hospitalizations and critical care costs. The April 2025 acquisition of Theravia from Mérieux Equity Partners broadened the rare disease portfolio, while Pedmarqsi and Xolremdi extend the oncology and specialty footprint.

Technology Platforms and Modalities

Norgine's pipeline spans multiple modalities including small molecules, polymer-based formulations, recombinant proteins, and radiopharmaceuticals, reflecting its licensing-led business model rather than a single proprietary platform. The company's Plenvu is a one-liter polyethylene glycol and ascorbate bowel preparation that addressed the tolerability limitations of larger-volume colonoscopy preparations. Its commercialization of Lymphoseek (technetium Tc 99m tilmanocept) via SpePharm AG demonstrates capability in radiopharmaceutical distribution for oncology sentinel node imaging.

Key Pipeline and Programs

Pedmarqsi (sodium thiosulfate solution for infusion) is Norgine's pediatric oncology asset licensed from Fennec Pharmaceuticals. It is indicated for the prevention of cisplatin-induced ototoxicity in patients aged one month to under 18 years with localized, non-metastatic solid tumors. Swissmedic granted marketing authorization in March 2026, and the product is already approved in Europe and commercialized in Australia and New Zealand.

Xolremdi received European Commission marketing approval in April 2026, adding another specialty product to the oncology and rare disease portfolio, though further clinical details remain to be disclosed by Norgine.

Through its 2025 in-licensing agreement with Vir Biotechnology, Norgine holds exclusive European, Australian, and New Zealand commercial rights to Vir's chronic hepatitis delta treatment candidate, with participation in a global cost-sharing arrangement for the ongoing ECLIPSE Phase III clinical development program. This program targets an area of significant unmet need, as chronic hepatitis delta is the most severe form of viral hepatitis and lacks broadly approved therapies.

Recent Developments

In March 2026, Swissmedic approved Pedmarqsi for cisplatin-induced ototoxicity prevention in pediatric patients, extending the product's regulatory footprint. April 2026 brought European Commission approval of Xolremdi. In April 2025, Norgine agreed to acquire Theravia, a French rare disease specialist formerly held by Mérieux Equity Partners, accelerating its push into orphan indications. The company also signed an exclusive in-licensing agreement with Vir Biotechnology in 2025, securing rights to the chronic hepatitis delta candidate across Europe, Australia, and New Zealand alongside global ECLIPSE trial cost-sharing.

Key Personnel

Janneke van der Kamp serves as Chief Executive Officer of Norgine, leading the company through its Goldman Sachs ownership era and a period of active portfolio expansion. Sandeep Sharma holds a senior leadership position within the executive team, contributing to strategic and operational direction. Fleur Herrenschmidt serves as Chief Legal Officer, overseeing legal affairs across Norgine's multi-territory commercial and licensing operations.

Strategic Partnerships

Norgine's growth model is built on in-licensing and co-commercialization deals with innovative developers. Key arrangements include the exclusive Pedmarqsi commercialization license from Fennec Pharmaceuticals covering Europe, Australia, and New Zealand, and the 2025 hepatitis delta licensing deal with Vir Biotechnology that includes global ECLIPSE trial cost-sharing. Norgine also holds a sublicense with Navidea Biopharmaceuticals for Lymphoseek in Europe, and has expanded Plenvu commercialization through deals in South Korea and multiple other territories.

FAQ Section

The European Commission approved Goldman Sachs's acquisition of Norgine Group in June 2024, providing the company with significant financial backing to accelerate deal-making. Since then, Norgine has completed or announced several portfolio-building transactions, including the Theravia acquisition in April 2025 and the Vir Biotechnology hepatitis delta licensing deal. The backing appears to have intensified Norgine's acquisitive posture without altering its core model of European specialty commercialization.

Chronic hepatitis delta, caused by the hepatitis D virus superimposed on hepatitis B infection, is the most severe form of chronic viral hepatitis and has historically had very limited approved treatment options. Norgine's deal with Vir Biotechnology grants it exclusive European, Australian, and New Zealand commercial rights to a late-stage candidate being evaluated in the ECLIPSE Phase III program. Success in ECLIPSE would give Norgine a first-mover commercial position in a rare but serious liver disease with high unmet need.

Norgine's century-long operating history and fully integrated commercial infrastructure across Europe, Australia, and New Zealand give it a distinctive execution capability that smaller in-licensors cannot replicate. Its model combines active business development — acquiring companies like Azanta and Theravia — with licensing deals that bring externally developed assets to market rapidly. This dual track of M&A and licensing, now supported by Goldman Sachs capital, positions Norgine as one of the most active mid-size deal-makers in European specialty pharma.

Pedmarqsi (sodium thiosulfate solution for infusion) is indicated for the prevention of cisplatin-induced ototoxicity in pediatric patients aged one month to under 18 years with localized, non-metastatic solid tumors. Licensed from Fennec Pharmaceuticals, the product obtained Swissmedic approval in March 2026, adding Switzerland to existing European and Australasian authorizations. It represents Norgine's clearest oncology support franchise and addresses a genuine quality-of-life gap in pediatric cancer care, where hearing loss from cisplatin chemotherapy can have lifelong consequences.

Gastroenterology and hepatology remain the historical core, anchored by bowel preparation agent Plenvu and rifaximin-α (Xifaxan) for hepatic encephalopathy. Oncology and rare diseases have grown substantially through Pedmarqsi, Xolremdi, and the Theravia acquisition. The Vir Biotechnology hepatitis delta deal reinforces hepatology, while the Azanta acquisition added women's healthcare and addiction medicine, giving Norgine one of the broader specialty portfolios among mid-size European pharma companies.

Norgine is primarily a late-stage and commercial-stage business, with Pedmarqsi and Xolremdi already approved and the Vir Biotechnology hepatitis delta candidate in the ongoing Phase III ECLIPSE trial. The company's licensing-led model means most clinical risk is borne by originator partners before Norgine assumes commercial rights. Near-term milestones include ECLIPSE Phase III data readouts for the hepatitis delta asset and the commercial integration of Theravia's rare disease products following the April 2025 acquisition close.

Key watchpoints for Norgine include the following:

ECLIPSE Phase III results for Vir Biotechnology's hepatitis delta candidate, which will determine the commercial value of Norgine's headline 2025 licensing deal across Europe, Australia, and New Zealand.
Successful integration of Theravia and delivery of its rare disease pipeline following the April 2025 acquisition from Mérieux Equity Partners.
Commercial uptake of Pedmarqsi across Swiss and broader European markets following the March 2026 Swissmedic approval and the April 2026 EC clearance of Xolremdi.
Broader partnership pipeline — Norgine's deal-making cadence has accelerated under Goldman Sachs ownership, and the terms and quality of future in-licensing transactions will be closely watched.
Execution risk across multiple simultaneous portfolio additions, spanning rare disease, hepatology, and pediatric oncology, which tests organizational capacity despite Norgine's integrated infrastructure.

Want to Update your Company's Profile?